176 related articles for article (PubMed ID: 14965363)
1. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer.
Kataoka H; Igarashi H; Kanamori M; Ihara M; Wang JD; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Maruyama K; Nakamura T; Arai H; Kajimura M; Hanai H; Tanaka M; Sugimura H
Cancer Sci; 2004 Feb; 95(2):136-41. PubMed ID: 14965363
[TBL] [Abstract][Full Text] [Related]
2. EPHA2/EFNA1 expression in human gastric cancer.
Nakamura R; Kataoka H; Sato N; Kanamori M; Ihara M; Igarashi H; Ravshanov S; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Konno H; Shinmura K; Tanaka M; Sugimura H
Cancer Sci; 2005 Jan; 96(1):42-7. PubMed ID: 15649254
[TBL] [Abstract][Full Text] [Related]
3. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma.
Cui XD; Lee MJ; Yu GR; Kim IH; Yu HC; Song EY; Kim DG
Int J Cancer; 2010 Feb; 126(4):940-9. PubMed ID: 19642143
[TBL] [Abstract][Full Text] [Related]
4. Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.
Toma MI; Erdmann K; Diezel M; Meinhardt M; Zastrow S; Fuessel S; Wirth MP; Baretton GB
PLoS One; 2014; 9(7):e102262. PubMed ID: 25025847
[TBL] [Abstract][Full Text] [Related]
5. EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.
Dunne PD; Dasgupta S; Blayney JK; McArt DG; Redmond KL; Weir JA; Bradley CA; Sasazuki T; Shirasawa S; Wang T; Srivastava S; Ong CW; Arthur K; Salto-Tellez M; Wilson RH; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2016 Jan; 22(1):230-242. PubMed ID: 26283684
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer.
De Robertis M; Loiacono L; Fusilli C; Poeta ML; Mazza T; Sanchez M; Marchionni L; Signori E; Lamorte G; Vescovi AL; Garcia-Foncillas J; Fazio VM
Clin Cancer Res; 2017 Jan; 23(1):159-170. PubMed ID: 27401248
[TBL] [Abstract][Full Text] [Related]
7. Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis.
Saito T; Masuda N; Miyazaki T; Kanoh K; Suzuki H; Shimura T; Asao T; Kuwano H
Oncol Rep; 2004 Mar; 11(3):605-11. PubMed ID: 14767510
[TBL] [Abstract][Full Text] [Related]
8. Expression of Eph receptors and their ligands, ephrins, during lipopolysaccharide fever in rats.
Ivanov AI; Steiner AA; Scheck AC; Romanovsky AA
Physiol Genomics; 2005 Apr; 21(2):152-60. PubMed ID: 15671251
[TBL] [Abstract][Full Text] [Related]
9. Soluble ephrin a1 is necessary for the growth of HeLa and SK-BR3 cells.
Alford S; Watson-Hurthig A; Scott N; Carette A; Lorimer H; Bazowski J; Howard PL
Cancer Cell Int; 2010 Oct; 10():41. PubMed ID: 20979646
[TBL] [Abstract][Full Text] [Related]
10. Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis.
Herath NI; Spanevello MD; Doecke JD; Smith FM; Pouponnot C; Boyd AW
Eur J Cancer; 2012 Mar; 48(5):753-62. PubMed ID: 21852108
[TBL] [Abstract][Full Text] [Related]
11. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N
BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143
[TBL] [Abstract][Full Text] [Related]
12. Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality.
Jukonen J; Moyano-Galceran L; Höpfner K; Pietilä EA; Lehtinen L; Huhtinen K; Gucciardo E; Hynninen J; Hietanen S; Grénman S; Ojala PM; Carpén O; Lehti K
Sci Rep; 2021 Apr; 11(1):8856. PubMed ID: 33893375
[TBL] [Abstract][Full Text] [Related]
13. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.
Ogawa K; Pasqualini R; Lindberg RA; Kain R; Freeman AL; Pasquale EB
Oncogene; 2000 Dec; 19(52):6043-52. PubMed ID: 11146556
[TBL] [Abstract][Full Text] [Related]
14. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.
Ishikawa M; Miyahara R; Sonobe M; Horiuchi M; Mennju T; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Huang CL; Date H
Lung Cancer; 2012 Jun; 76(3):431-8. PubMed ID: 22236865
[TBL] [Abstract][Full Text] [Related]
15. SOCS2 Binds to and Regulates EphA2 through Multiple Mechanisms.
Pilling C; Cooper JA
Sci Rep; 2017 Sep; 7(1):10838. PubMed ID: 28883622
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells.
Potla L; Boghaert ER; Armellino D; Frost P; Damle NK
Cancer Lett; 2002 Jan; 175(2):187-95. PubMed ID: 11741747
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma.
Wu D; Suo Z; Kristensen GB; Li S; Troen G; Holm R; Nesland JM
Gynecol Oncol; 2004 Aug; 94(2):312-9. PubMed ID: 15297167
[TBL] [Abstract][Full Text] [Related]
18. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.
Ireton RC; Chen J
Curr Cancer Drug Targets; 2005 May; 5(3):149-57. PubMed ID: 15892616
[TBL] [Abstract][Full Text] [Related]
19. Human dendritic cells express neuronal Eph receptor tyrosine kinases: role of EphA2 in regulating adhesion to fibronectin.
de Saint-Vis B; Bouchet C; Gautier G; Valladeau J; Caux C; Garrone P
Blood; 2003 Dec; 102(13):4431-40. PubMed ID: 12907451
[TBL] [Abstract][Full Text] [Related]
20. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis.
Nakamoto M; Bergemann AD
Microsc Res Tech; 2002 Oct; 59(1):58-67. PubMed ID: 12242697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
